Preclinical data show potential for Genprex's nanoparticle delivery system
Genprex and its collaborators have published positive preclinical data about the use of Genprex's Oncoprex, a nanoparticle delivery system for the delivery of a FAS DNA plasmid to treat metastatic colorectal cancer. Read More
Biogen reaches agreement with Samsung Biologics
Biogen has reached an agreement with Samsung Biologics to sell an equity stake in the companies' biosimilar joint venture for up to $2.3 billion. Biogen and Samsung Biologics have built an anti-tumor necrosis factor portfolio in Europe. Read More
Oxford Biomedica broadens viral vector offerings
Oxford Biomedica and Homology Medicines have agreed to establish a high-performing, full scope, adeno-associated virus manufacturing and innovation business in the U.S. The agreement is accretive to Oxford Biomedica's revenue growth, with contribution from Homology and the potential future customer pipeline. Read More
Charles River expands strategic partnership with SAMDI Tech
Charles River Laboratories has expanded its strategic partnership with SAMDI Tech. The expanded agreement will provide Charles River's clients seamless access to the label-free, high-throughput screening mass spectrometry platform in drug discovery. Read More
Broad Sky Partners acquires Thomas Scientific
Broad Sky Partners stated a strategic investment from Capital Constellation as well as its acquisition of Thomas Scientific. Read More
Septerna launches with $100M series A financing
Septerna has launched with $100 million in series A financing. The financing will enable the company to advance its emerging pipeline of novel G protein-coupled receptor-targeted drug programs. Read More
Atara Biotherapeutics partners with Fujifilm on cell therapy manufacturing
Atara Biotherapeutics has entered into a long-term strategic agreement with Fujifilm under which Fujifilm will acquire Atara's T-cell operations and manufacturing facility in Thousand Oaks, CA, for $100 million upfront, retaining Atara's current staff at the site. The firms will also enter a long-term supply agreement, which could extend to 10 years. Read More
Adimab launches four novel antibody-based technologies
Adimab has expanded its proprietary technologies available for use in drug development. The expansion will aid in the development of antibody and multispecific therapeutic modalities, the firm said. Read More
Active Motif acquires Amaryllis Nucleics
Active Motif has purchased Amaryllis Nucleics, a startup focused on proprietary RNA sequencing methods. Read More
Ractigen Therapeutics obtains $30M to develop RNAa platform
Ractigen Therapeutics has received $30 million in a series A financing round. Ractigen will use the proceeds to advance several programs from the preclinical to clinical phase as well as to scale up its oligonucleotide manufacturing capabilities. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
